Wuhan Hvsen Biotechnology Co.,Ltd. Stock Price

SZSE:300871 Community·CN¥3.9b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

300871 Share Price Performance

CN¥0

-12.57 (-100.00%)

CN¥0

-12.57 (-100.00%)

CN¥0

Fri, 5 Dec 25

Share Pricen/a

300871 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Undervalued with excellent balance sheet.

2 Risks

4 Rewards

View Full Analysis

Wuhan Hvsen Biotechnology Co.,Ltd. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: 1.07
: 26.04%
: 12.92%
: 14.7%

View Full Analysis

About 300871

Founded: 2002
Employees: 1028
CEO: Jie Han
WebsiteView website: www.whhsyy.com

Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founded in 2002 and is based in Wuhan, China.